Intelligence · Clinical Development
Pipeline search results
Programs matching “oncology” across our ClinicalTrials.gov index — phase, modality, sponsor, and trial IDs.
Quick answer
Showing 189 pipeline programs matching "oncology" from NovaPharmaNews Clinical Development Intelligence — phase, modality, sponsor, and ClinicalTrials.gov trial IDs.
Refine search
Search results
-
ALX2004
ALX ONCOLOGY HOLDINGS INC
NSCLC (Advanced Non-small Cell Lung Cancer)
1 trial -
BBO-10203
BridgeBio Oncology Therapeutics
Solid Tumor, Adult
1 trial -
BBO-11818
BridgeBio Oncology Therapeutics
Non-Small Cell Lung Cancer
1 trial -
BBO-8520
BridgeBio Oncology Therapeutics
Non-small Cell Lung Cancer
1 trial -
BBP-398
BridgeBio Oncology Therapeutics
Solid Tumor, Adult
1 trial -
BBP-398 (Formerly known as IACS-15509)
BridgeBio Oncology Therapeutics
Tumor, Solid
1 trial -
BBP-398 with nivolumab
BridgeBio Oncology Therapeutics
Non Small Cell Lung Cancer
1 trial -
BBP-671
BridgeBio Oncology Therapeutics
Healthy Volunteers
1 trial -
BBP-711
BridgeBio Oncology Therapeutics
Healthy
1 trial -
C19-A3 GNP
Cardiff Oncology
Type 1 Diabetes
1 trial -
CG0070
CG Oncology
Muscle-Invasive Bladder Carcinoma
1 trial -
CHS-006 (anti-TIGIT)
Coherus Oncology
Advanced Solid Tumor
1 trial -
CHS-1000
Coherus Oncology
Advanced or Metastatic Solid Tumors
1 trial -
CHS-114
Coherus Oncology
Metastatic Solid Tumor
1 trial -
CHS-114
Coherus Oncology
Advanced Solid Tumor
1 trial -
CHS-1701
Coherus Oncology
Healthy
1 trial -
CHS-1701
Coherus Oncology
Bioequivalence
1 trial -
CHS-1701
Coherus Oncology
Immunity, Humoral
1 trial -
CHS-388
Coherus Oncology
Advanced Solid Tumor
1 trial -
Cobimetinib
Cardiff Oncology
Locally Advanced Pancreatic Ductal Adenocarcinoma
1 trial -
Darlifarnib
Kura Oncology
Solid Tumors With HRAS Alterations
1 trial -
Dose dense re-challenge of high dose methotre...
Pari Pharma GmbH
Oncology: RELAPSED PRIMARY CNS LYMPHOMA
1 trial -
Evorpacept
ALX ONCOLOGY HOLDINGS INC
Bladder Cancer
1 trial -
Evorpacept (ALX148)
ALX ONCOLOGY HOLDINGS INC
Metastatic Cancer
1 trial
Frequently asked questions
What is the Clinical Development Intelligence Platform?
It is NovaPharmaNews pipeline intelligence hub covering 20,548 clinical development programs — not just a directory. It includes phase distribution dashboards, therapeutic area overviews, NDA/BLA watchlists, upcoming readouts, company pipeline rankings, competitive landscape maps, and personalized watchlists.
How does this compare to Evaluate Pharma or Citeline?
Like Evaluate Pharma and Citeline Trialtrove, we index ClinicalTrials.gov programs by sponsor, phase, and indication. Our platform adds cross-links to NovaPharmaNews company profiles, drug INN pages, patents, and congress readout calendars — improving crawl depth and reducing orphan program pages.
Where does pipeline data come from?
Program records derive from ClinicalTrials.gov and link to sponsor company profiles. Trial status and phase reflect registry data at last sync — verify on ClinicalTrials.gov before investment decisions. See our data sources page for attribution.
Can I follow a company or program for updates?
Yes — use the watchlist forms on this page to follow sponsors, individual programs, disease clusters, or therapeutic areas. Alerts use the same subscription infrastructure as our events intelligence hub.